Kaempferol attenuates angiotensin II-induced myocardial fibrosis in association with macrophage glycolytic and PKM2/HIF-1α signaling changes

Introduction Myocardial fibrosis develops through sustained interactions among activated fibroblasts, infiltrating immune cells, and metabolic signals within the injured myocardium. This study evaluated whether kaempferol attenuated angiotensin II (Ang II)-induced myocardial fibrosis in association with changes in macrophage pyruvate kinase M2 (PKM2)/hypoxia-inducible factor 1α (HIF-1α)-linked glycolytic and inflammatory activation. Methods The primary in vivo cohort comprised 48 male C57BL/6J mice randomized to four groups (12 per group) and treated for 28 days. Separate exploratory cohorts comprised 48 mice assigned to a dose-response/positive-comparator study and 42 mice assigned to single-dose plasma and myocardial exposure profiling. Donor-matched bone marrow-derived macrophages from six additional mice were studied under eight conditions incorporating kaempferol, PKM2 overexpression, Pkm2 knockdown, and matched controls. Results In the primary cohort, kaempferol reduced interstitial collagen volume fraction from 16.07% ± 2.10% to 9.14% ± 2.26% and increased left ventricular ejection fraction from 48.01% ± 2.97% to 56.87% ± 2.56%. In the separate dose-response cohort, collagen volume fraction declined from 16.00% ± 2.10% with Ang II + vehicle to 13.70% ± 1.90%, 11.20% ± 1.80%, and 9.20% ± 2.00% with kaempferol at 2.5, 5, and 10 mg/kg/day, respectively; the losartan comparator group had a value of 8.60% ± 1.70%. Plasma kaempferol concentration was highest at the 0.5-h sampling point and myocardial concentration at 1 h after a single 10 mg/kg intraperitoneal dose. In macrophages, kaempferol reduced glycolytic and inflammatory readouts and weakened conditioned-medium-induced fibroblast activation. Fibroblast protein measurements showed partial restoration of α-smooth muscle actin (α-SMA) and collagen I abundance with PKM2 overexpression and lower abundance after Pkm2 knockdown. Discussion These findings support an antifibrotic action associated with reduced inflammatory macrophage enrichment and suppression of PKM2/HIF-1α-linked glycolytic activation, while not establishing PKM2 as a direct kaempferol target or the pathway as the sole mediator of cardioprotection. Because kaempferol may exhibit assay-dependent interference or nonspecific biological effects, the in vitro findings and putative pathway involvement require cautious interpretation; the available data do not demonstrate direct PKM2 engagement or clinical efficacy.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-18
DOI
https://doi.org/10.3389/fphar.2026.1986346
Primary Topic
Cardiac Fibrosis and Remodeling
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Kaempferol attenuates angiotensin II-induced myocardial fibrosis in association with macrophage glycolytic and PKM2/HIF-1α signaling changes

Ming Zhang, Fei Qi, Zhengbo Zhu, Qian Zhou et al.
Frontiers in Pharmacology
Cardiac Fibrosis and Remodeling
article

Kaempferol attenuates angiotensin II-induced myocardial fibrosis in association with macrophage glycolytic and PKM2/HIF-1α signaling changes

Ming Zhang, Fei Qi, Zhengbo Zhu, Qian Zhou, Hanli Li
article en

Abstract

Introduction Myocardial fibrosis develops through sustained interactions among activated fibroblasts, infiltrating immune cells, and metabolic signals within the injured myocardium. This study evaluated whether kaempferol attenuated angiotensin II (Ang II)-induced myocardial fibrosis in association with changes in macrophage pyruvate kinase M2 (PKM2)/hypoxia-inducible factor 1α (HIF-1α)-linked glycolytic and inflammatory activation. Methods The primary in vivo cohort comprised 48 male C57BL/6J mice randomized to four groups (12 per group) and treated for 28 days. Separate exploratory cohorts comprised 48 mice assigned to a dose-response/positive-comparator study and 42 mice assigned to single-dose plasma and myocardial exposure profiling. Donor-matched bone marrow-derived macrophages from six additional mice were studied under eight conditions incorporating kaempferol, PKM2 overexpression, Pkm2 knockdown, and matched controls. Results In the primary cohort, kaempferol reduced interstitial collagen volume fraction from 16.07% ± 2.10% to 9.14% ± 2.26% and increased left ventricular ejection fraction from 48.01% ± 2.97% to 56.87% ± 2.56%. In the separate dose-response cohort, collagen volume fraction declined from 16.00% ± 2.10% with Ang II + vehicle to 13.70% ± 1.90%, 11.20% ± 1.80%, and 9.20% ± 2.00% with kaempferol at 2.5, 5, and 10 mg/kg/day, respectively; the losartan comparator group had a value of 8.60% ± 1.70%. Plasma kaempferol concentration was highest at the 0.5-h sampling point and myocardial concentration at 1 h after a single 10 mg/kg intraperitoneal dose. In macrophages, kaempferol reduced glycolytic and inflammatory readouts and weakened conditioned-medium-induced fibroblast activation. Fibroblast protein measurements showed partial restoration of α-smooth muscle actin (α-SMA) and collagen I abundance with PKM2 overexpression and lower abundance after Pkm2 knockdown. Discussion These findings support an antifibrotic action associated with reduced inflammatory macrophage enrichment and suppression of PKM2/HIF-1α-linked glycolytic activation, while not establishing PKM2 as a direct kaempferol target or the pathway as the sole mediator of cardioprotection. Because kaempferol may exhibit assay-dependent interference or nonspecific biological effects, the in vitro findings and putative pathway involvement require cautious interpretation; the available data do not demonstrate direct PKM2 engagement or clinical efficacy.

Frontiers in PharmacologyVol. 17
Hefei University of Technology (CN), Hefei University (CN), Anhui Institute of Medicine (CN)
Good health and well-being
Cardiac Fibrosis and Remodeling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon